Other News To Note

Regulus Therapeutics Inc., of La Jolla, Calif., identified a third microRNA target in its alliance with GlaxoSmithKline plc (GSK), of London, triggering a preclinical milestone payment from GSK. Under the alliance, Regulus has the potential to earn more than $600 million in payments, including license and milestone payments and tiered royalties up to double digits on worldwide sales.